Thursday, March 28, 2024
ADVT 
International

Pfizer: Mid-November earliest it can seek virus vaccine OK

Darpan News Desk The Canadian Press, 16 Oct, 2020 06:39 PM
  • Pfizer: Mid-November earliest it can seek virus vaccine OK

Pfizer Inc. cannot request emergency authorization of its COVID-19 vaccine before the third week of November -- and that’s if everything goes well, the company’s CEO announced Friday.

Despite President Donald Trump’s repeated promises of a vaccine before Election Day, scientists have been cautioning that it’s unlikely data showing a leading shot actually works would come until November or December.

Another leading U.S. contender, Moderna Inc., previously announced the earliest it could seek authorization of its own vaccine would be Nov. 25.

Pfizer CEO Albert Bourla has long said it's possible testing might reveal by the end of October if his company’s vaccine actually protects against the coronavirus. But in Friday’s announcement, he made clear that effectiveness is only part of the equation.

The vaccine also must be proven safe. And to qualify for an “emergency use authorization,” any COVID-19 vaccine must track at least half the participants in large-scale studies for two months after their second dose, the time period in which side effects are likely to appear.

Bourla estimated Pfizer's 44,000-person study will reach that milestone in the third week of November.

“We are operating at the speed of science,” he wrote in a letter posted to the company’s website.

The vaccine made by Pfizer and its German partner BioNTech are among several leading candidates in final testing.

Even if a vaccine emerges by year’s end, only limited doses will be available right away. The U.S. government is deciding who would be first in line, almost certainly health care workers, and estimates there may be enough for widespread vaccinations in the spring.

MORE International ARTICLES

Macy's plans smaller but camera-ready Thanksgiving parade

Macy's plans smaller but camera-ready Thanksgiving parade
Macy's similarly remade its traditional July Fourth fireworks show this year, swapping the big one-night spectacle for a series of smaller fireworks displays.

Macy's plans smaller but camera-ready Thanksgiving parade

Trump, DeVos raise school choice in appeal to vexed parents

Trump, DeVos raise school choice in appeal to vexed parents
For Trump, it’s seen as a potential lifeline to Black and Hispanic voters, who are more likely to support vouchers and other school choice options, polls have found.

Trump, DeVos raise school choice in appeal to vexed parents

Norad leaders call for 'layered defence'

Norad leaders call for 'layered defence'
Fesler and O'Shaughnessy say adversaries like Russia and China are increasingly well-positioned to exploit the "seams" that currently exist between North America's air, sea and missile defence systems and early warning networks.

Norad leaders call for 'layered defence'

Trump follows Biden to battleground Michigan

Trump follows Biden to battleground Michigan
Biden plans stiff tax penalties for companies that manufacture U.S.-bound products outside the country and a crackdown on those that use offshoring to avoid paying taxes at home.

Trump follows Biden to battleground Michigan

Biden in Michigan to talk Buy American

Biden in Michigan to talk Buy American
If elected, Biden said, he would impose stiff new tax penalties on companies that manufacture U.S.-bound products outside the country, create incentives for keeping jobs on U.S. soil and close what he called "Trump loopholes" that allow companies engaged in offshoring to avoid paying U.S. taxes.

Biden in Michigan to talk Buy American

AstraZeneca vaccine trial not going ahead due to adverse reaction in a subject

AstraZeneca vaccine trial not going ahead due to adverse reaction in a subject
A spokesperson for AstraZeneca, via a statement said that the company’s “standard review process triggered a pause to vaccination to allow review of safety data.”

AstraZeneca vaccine trial not going ahead due to adverse reaction in a subject